Floatz logo

Cediranib

B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma

Mayo ClinicSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
University of California, Davis
Phase 2BB
Cytosin-Arabinosid
University of California, Davis
Phase 2B
Solu-Cortef
Northwestern University
Phase 1/2CCC
METHOTREXATE
Northwestern University
Phase 1/2CCC
mln9708
Northwestern University
Phase 1/2CCC
Pomalidomide
Mayo Clinic
Phase 1CC

Same molecule, other indications

Cediranib is also rated in:

gliosarcomaDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent NeuroblastomaDormant
BBB
Indicative ·
73 / 100
View asset →
Recurrent Colon CancerDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →